+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Osteoporosis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

  • PDF Icon

    Report

  • 375 Pages
  • August 2022
  • Region: Global
  • Global Markets Direct
  • ID: 5654056
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Drugs In Development, 2022, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 6, 23, 10, 20, 3, 66, 19 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 13 and 14 molecules, respectively.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Report Coverage
  • Osteoporosis - Overview
  • Osteoporosis - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Osteoporosis - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Osteoporosis - Companies Involved in Therapeutics Development
  • Osteoporosis - Drug Profiles
  • Osteoporosis - Dormant Projects
  • Osteoporosis - Discontinued Products
  • Osteoporosis - Product Development Milestones
  • Featured News & Press Releases
  • Aug 10, 2022: Rani Therapeutics announces positive topline results from phase 1 study of RT-102 in osteoporosis
  • Aug 08, 2022: Rani Therapeutics enters into $45 million loan agreement to support ongoing Ramipril platform advancement and clinical pipeline development
  • Jul 20, 2022: Alvotech initiates a pharmacokinetic study for AVT03, a proposed biosimilar for Prolia and Xgeva
  • Jul 20, 2022: Henlius Denosumab Biosimilar HLX14 received clinical trial approval in Australia for the phase 3 MRCT
  • Jul 18, 2022: Entera Bio announces execution of key regulatory milestones for EB613, the first oral anabolic drug proposed for the treatment of Osteoporosis; Miranda Toledano assumes CEO Position
  • Jun 17, 2022: Voluntary announcement - First patient has been dosed in an international multicentre phase 3 clinical trial for a biosimilar of denosumab HLX14 (recombinant anti-RANKL human monoclonal antibody injection) for the treatment of postmenopausal osteoporosis in women with high fracture risks in Mainland China
  • Jun 08, 2022: Radius Health expands Non-US market footprint for TYMLOS
  • Jun 01, 2022: Radius Health update on Abaloparatide Transdermal System
  • May 03, 2022: Rani Therapeutics’ RaniPill capsule named winner in the Health category of fast company’s 2022 World Changing Ideas Awards
  • Apr 29, 2022: Transcenta doses first subject in Phase I osteoporosis drug trial in China
  • Apr 01, 2022: Thousands of people set to benefit from first new treatment for osteoporosis for over a decade
  • Mar 23, 2022: Rani Therapeutics announces initiation of phase 1 study of RT-102 oral PTH for osteoporosis
  • Mar 10, 2022: Amgen keeps dominating Korea’s osteoporosis treatment market
  • Mar 01, 2022: Radius Health files sNDA for TYMLOS in Men with osteoporosis
  • Feb 17, 2022: Entera Bio to present at Aegis Virtual Conference on February 23rd
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development for Osteoporosis, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Products under Development by Companies, 2022
  • Products under Development by Universities/Institutes, 2022
  • Number of Products by Stage and Target, 2022
  • Number of Products by Stage and Mechanism of Action, 2022
  • Number of Products by Stage and Route of Administration, 2022
  • Number of Products by Stage and Molecule Type, 2022
  • Osteoporosis - Dormant Projects, 2022
  • Osteoporosis - Discontinued Products, 2022
List of Figures
  • Number of Products under Development for Osteoporosis, 2022
  • Number of Products under Development by Companies, 2022
  • Number of Products under Development by Universities/Institutes, 2022
  • Number of Products by Top 10 Targets, 2022
  • Number of Products by Stage and Top 10 Targets, 2022
  • Number of Products by Top 10 Mechanism of Actions, 2022
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2022
  • Number of Products by Routes of Administration, 2022
  • Number of Products by Stage and Routes of Administration, 2022
  • Number of Products by Top 10 Molecule Types, 2022
  • Number of Products by Stage and Top 10 Molecule Types, 2022

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abiogen Pharma SpA
  • Ablynx NV
  • Abreos Biosciences Inc
  • Aclaris Therapeutics Inc
  • Addpharma Inc
  • Aerami Therapeutics Inc
  • Affilogic SAS
  • AgeX Therapeutics Inc
  • Airsea (Taizhou) Pharmaceutical Ltd
  • AlphaMab Co Ltd
  • Alvotech SA
  • Amgen Inc
  • Amogen Pharma Pvt Ltd
  • Angitia Biopharmaceuticals
  • Aryogen Pharmed Co
  • Aveta Biomics Inc
  • Bainan Biotech ApS
  • Beijing Kangleweishi Biotechnology Co Ltd
  • Beijing Northland Biotech Co Ltd
  • Beryl Therapeutics Inc
  • Better Life Pharmaceuticals Inc
  • Biocon Ltd
  • Bone Biologics Corp
  • Cellatoz Therapeutics Inc
  • Celltrion Inc
  • China NT Pharma Group Co Ltd
  • ChoDang Pharm Co Ltd
  • Citragen Pharmaceuticals Inc
  • CK Regeon Inc
  • Clayton Biotechnologies Inc
  • Clonz Biotech Pvt Ltd
  • Corium Inc
  • CSPC Pharmaceutical Group Ltd
  • Curexsys GmbH
  • Daewoong Pharmaceutical Co Ltd
  • Dongkook Pharmaceutical Co Ltd
  • Eden Biologics Inc
  • Eli Lilly and Co
  • Endoceutics Inc
  • Enesi Pharma Ltd
  • Entera Bio Ltd
  • Enteris BioPharma Inc
  • Enzene Biosciences Ltd
  • Enzo Biochem Inc
  • Epygen Biotech Pvt Ltd
  • Evgen Pharma Plc
  • Fresenius Kabi SwissBioSim GmbH
  • Galapagos NV
  • Gbiologics Inc
  • Gedeon Richter Plc
  • Genor BioPharma Co Ltd
  • Genu Pharma Co Ltd
  • GlycoNex Inc
  • GPN Therapeutics Inc
  • Haoma Medica Ltd
  • Helixmith Co Ltd
  • Histide AG
  • HNB Therapeutics LLC
  • Hualan Biological Engineering Inc
  • Huons Global Co Ltd
  • IMGENEX India Pvt Ltd
  • Immunwork Inc
  • InnoPharmaScreen Inc
  • Intas Pharmaceuticals Ltd
  • Ipsen SA
  • Jiangsu Hansoh Pharmaceutical Group Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Jiangsu T-mab BioPharma Co Ltd
  • Keros Therapeutics Inc
  • Kyoto Pharmaceutical Industries Ltd
  • Lactocore Inc
  • LBL Biotech Corp
  • Lead Discovery Center GmbH
  • LEXEO Therapeutics LLC
  • Link Biologics Ltd
  • Lupin Ltd
  • Luye Pharma Group Ltd
  • Mabxience Holding SL
  • Max Biopharma Inc
  • Merck & Co Inc
  • Mesentech Inc
  • Mezomax Inc
  • Nano Intelligent Biomedical Engineering Corp
  • Nanomedic Inc
  • NeuClone Pty Ltd
  • NovMetaPharma Co Ltd
  • Omeros Corp
  • Oncosimis Biotech Pvt Ltd
  • Ortho Regenics Pvt Ltd
  • OssiFi Inc
  • Paras Biopharmaceuticals Finland Oy
  • PhytoHealth Corp
  • Prestige BioPharma Ltd
  • PRG S&Tech Inc
  • Qilu Pharmaceutical Co Ltd
  • Radius Health Inc
  • Rani Therapeutics LLC
  • Regenerative Arthritis & Bone Medicine Inc
  • Reliance Life Sciences Pvt Ltd
  • Reven Holdings Inc
  • Ribomic Inc
  • Samsung Bioepis Co Ltd
  • Sandoz International GmbH
  • Shaanxi Micot Technology Co Ltd
  • Shandong New Time Pharmaceutical Co Ltd
  • Shanghai Celgen Bio-Pharmaceutical Co Ltd
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Shanghai Henlius Biotech Inc
  • Shanghai Junshi Bioscience Co Ltd
  • Shanghai Mab Venture Biopharm Co Ltd
  • Shenzhen Salubris Pharmaceuticals Co Ltd
  • Shin Poong Pharm Co Ltd
  • Stelis Biopharma Ltd
  • Surrozen Inc
  • Suzhou Stainwei Biotech Inc
  • Taithera Inc
  • Takeda Pharmaceutical Co Ltd
  • Tempest Therapeutics Inc
  • Teva Pharmaceutical Industries Ltd
  • The National Institute for Biotechnology in the Negev Ltd
  • The United Laboratories International Holdings Ltd
  • Tritech Biopharmaceuticals Co Ltd
  • TSH Biopharm Corporation Ltd
  • Uni-Bio Science Group Ltd
  • Vibe Pharmaceuticals LLC
  • Vidasym Inc
  • Viking Therapeutics Inc
  • Wuxi Hebang Biotechnology Co Ltd
  • Yooyoung Pharm Co Ltd
  • Zosano Pharma Corp
  • Zydus Lifesciences Ltd